Company intelligence / Profile preview
Toagosei
Minato-ku, Tokyo, Japantoagosei.co.jp ↗
- Ownership
- Private
- Employees
- ~2411
- Development stage
- Other
01
Overview
Toagosei is developing next-generation Cell Penetrating Peptide (CPP)-based drug delivery systems and peptide-drug conjugates for targeted delivery, particularly for hard-to-reach tissues like the brain, in collaboration with The University of Tokyo, aimed at addressing oncology, neurology, and other diseases in early-stage research.
- Therapeutic areas
- OncologyNeurologyInfectious DiseasesRare Diseases
- Modalities
- Peptide-drug conjugateSmall molecule
- Industry
- Chemicals & Materials
02
Drug pipeline
1 asset03
Partnerships
ToyotaThe University of Tokyo
Beyond the preview
Go deeper on Toagosei.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Toagosei.